Sees FY25 gross profit margin in the 71%-73% range. In addition, the company expects FY25 operating expenses in the range of $165M-$170M, including non-cash stock-based compensation expense guidance in the range of $22M-$25M. “In 2025, we expect adoption for the RxSight (RXST) system to remain strong as we collaborate with a diverse range of customers to further expand the infrastructure for post-operative light treatments. Building on our momentum in North America, we also look forward to entering key international markets in Asia and Europe. Finally, leveraging the foundation established since our initial FDA approval, we plan to continue to innovate the RxSight system, that we believe will continue to set the standard for the premium IOL market for years to come,” said Ron Kurtz, Chief Executive Officer and President of RxSight.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.